Navigation Links
NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
Date:10/25/2007

EMERYVILLE, Calif., Oct. 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (Amex, TSX: NBY) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of U.S. $4.00 per share. NovaBay has granted to the underwriters a 30-day option to purchase up to an additional 750,000 shares at the initial public offering price to cover over-allotments, if any. The shares will commence trading on October 26, 2007 on the American Stock Exchange and on an "if, as and when issued" basis on the Toronto Stock Exchange, under the symbol "NBY". The offering is expected to close on or about October 31, 2007.

Dundee Securities Corporation is acting as the sole book runner for the offering, with Desjardins Securities Inc. as co-lead manager. The shares are being offered in Canada by an underwriting syndicate co-led by Dundee Securities Corporation and Desjardins Securities Inc. and including Blackmont Capital Inc., and in the United States by Dundee Securities Inc. and Dawson James Securities, Inc.

The offering is being made in the United States pursuant to a written prospectus forming a part of the registration statement relating to these securities, which was declared effective by the Securities and Exchange Commission on October 24, 2007, and in Canada pursuant to a final base PREP prospectus dated October 24, 2007 for which a receipt has been issued by the applicable Canadian securities regulatory authorities and which shall be supplemented by a supplemented PREP prospectus. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, and there shall be no sale of these securities in any state, province or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province or jurisdiction.

Copies of the United States prospectus may be obtained from Dawson James Securities, Inc., Attn: Investment Banking, 925 South Federal Highway, 6th Floor, Boca Raton, FL 33432, telephone number (866) 928-0928. Copies of the Canadian prospectus may be obtained from Dundee Securities Corporation, 1 Adelaide St. E., Suite 2700, Toronto, Ontario M4T 1J9; Attn: Equity Capital Markets, E-mail: ecm@dundeesecurities.com.

About NovaBay

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus (MRSA). NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide compounds in the eye, ear and sinus and in contact lens solutions and a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NovaBay's NeutroPhase product in woundcare applications.

NovaBay(TM), Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay Pharmacuticals, Inc. All other trademarks and trade names are the property of their respective owners.

Safe Harbor Statement

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay's product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.


'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Corn prices and ethanol: Are the markets flaky - or working as they should?
4. Alliant to add 100 megawatts of wind power by 2005, raise gas prices
5. QBIs PreserveX product passes initial test
6. 2006: A great biotech financing year, unless you were going public!
7. TomoTherapys 100th radiology system reaches public sector
8. With patents and research tools, when is private really public?
9. Brady Corp. raises $137 million in public offering
10. In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde
11. Republican sees nothing wrong with Doyles use of executive order
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
(Date:3/23/2017)... , March 23, 2017 NetworkNewsWire ... ... death, putting significant strain on health care systems, in terms ... diagnoses rises, so too does the development of innovative and ... side effects. Among the many types of cancer treatments, a ...
(Date:3/23/2017)... La. (PRWEB) , ... March 23, 2017 , ... ... industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as ... customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):